A provision in the current appropriations bill would allow Medicare to cover multi‑cancer early detection (MCED) tests after FDA approval without awaiting US Preventive Services Task Force endorsement. The proposal sets reimbursement equal to existing multi‑target stool DNA screening (~$509), phases in eligibility from age 50 in 2029 upward, and aims to accelerate commercial adoption of MCED diagnostics. Stakeholders note the change could materially affect market access and payer strategies for liquid‑biopsy companies.